Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03433469 · ClinicalTrials.gov registry record · Phase 2

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

A Phase 2 study of Stage IIIA Non-Small Cell Lung Cancer and Stage I Non-Small Cell Lung Cancer, sponsored by University of California, San Francisco.

Active
Registry status
Phase 2
Development phase
27
Enrollment target
3
Study locations

NCT03433469 is a Phase 2 study of Stage IIIA Non-Small Cell Lung Cancer and Stage I Non-Small Cell Lung Cancer that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 27 participants, below the 33-participant average among 10 other Stage IIIA Non-Small Cell Lung Cancer trials with a reported enrollment target (18% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03433469, a Phase 2 study of Stage IIIA Non-Small Cell Lung Cancer and Stage I Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by University of California, San Francisco.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
27 participants
Enrollment target
3
Study locations

Study Summary

This phase II trial studies how well osimertinib works in treating participants with stage I-IIIA Epithelial Growth Factor Receptor (EGFR) -mutant non-small cell lung cancer before surgery. Osimertinib may stop the growth of tumor cells by blocking mutant EGFR signaling in cancer cells.

Conditions Studied

Stage IIIA Non-Small Cell Lung Cancer Stage I Non-Small Cell Lung Cancer Stage II Non-Small Cell Lung Cancer Stage IIA Non-Small Cell Lung Cancer Stage IIB Non-Small Cell Lung Cancer Stage IA Non-Small Cell Lung Cancer Stage IB Non-Small Cell Lung Cancer

Interventions

  • DRUG Osimertinib
  • PROCEDURE Therapeutic Conventional Surgery

Study Locations (3)

California

  • University of California, Davis - Davis
  • University of California, San Francisco - San Francisco

Colorado

  • University of Colorado - Aurora

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2018-07-31
Est. Completion 2026-10-31
Phase Phase 2

Sponsor

University of California, San Francisco

1,713 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03433469

The ClinicalTrials.gov registry entry for NCT03433469 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 33-participant average among 10 other Stage IIIA Non-Small Cell Lung Cancer trials with a reported enrollment target (18% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Stage IIIA Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Osimertinib is the first listed.

NCT03433469 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Colorado.

Frequently Asked Questions

What is clinical trial NCT03433469 about?

NCT03433469 is a clinical study titled "Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery". This phase II trial studies how well osimertinib works in treating participants with stage I-IIIA Epithelial Growth Factor Receptor (EGFR) -mutant non-small cell lung cancer before surgery. Osimertinib may stop the growth of tumor cells by blocking mutant EGFR signaling in cancer cells.

What is the current status of trial NCT03433469?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2018-07-31. Estimated completion is 2026-10-31.

What conditions does trial NCT03433469 study?

This clinical trial studies the following conditions: Stage IIIA Non-Small Cell Lung Cancer, Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT03433469?

The interventions under investigation include: Osimertinib (DRUG), Therapeutic Conventional Surgery (PROCEDURE).

Who is sponsoring clinical trial NCT03433469?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03433469 being conducted?

This trial has 3 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IIIA Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage IIIA Non-Small Cell Lung Cancer

All registered trials for this condition

Stage I Non-Small Cell Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.